ADAPTIVE TCR CORPORATION

Company Information

Company Name
ADAPTIVE TCR CORPORATION
Address
1551 Eastlake Avenue East
Suite 200
SEATTLE, WA, 98102-
Phone
1 --
URL
n/a
DUNS
832591544
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$1,213,074.00
4
SBIR Phase II
$2,528,467.00
1
Chart code to be here

Award List

  1. Development of T-cell receptor repertoire profiling as a diagnostic for T1D

    Amount: $632,685.00

    DESCRIPTION (provided by applicant): The goal of this Phase I project is the identification of a molecular signature in the T-cell receptor repertoire of early-stage Type 1 Diabetes (T1D) patients th ...

    SBIR Phase I 2010 Department of Health and Human Services
  2. Correlating TCR diversity to immune reconstitution after cord blood transplant

    Amount: $148,999.00

    DESCRIPTION (provided by applicant): The goal of this Phase I project is to develop a method to objectively measure immune reconstitution following hematopoietic stem cell transplantation using direc ...

    SBIR Phase I 2011 Department of Health and Human Services
  3. Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling

    Amount: $165,191.00

    DESCRIPTION (provided by applicant): Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling T-cell neoplasms are generally more aggressive and have poorer outcomes than comparable ...

    SBIR Phase I 2013 Department of Health and Human Services
  4. Correlating TCR diversity to immune reconstitution after cord blood transplant

    Amount: $2,528,467.00

    DESCRIPTION (provided by applicant): Many patients requiring stem cell transplantation for hematological malignancies are unable to find a suitable HLA-matched sibling or unrelated donor. Transplants ...

    SBIR Phase II 2013 Department of Health and Human Services
  5. SBIR TOPIC 315: DEVELOPMENT OF COMPANION DIAGNOSTICS: ENABLING PRECISION MEDICINE

    Amount: $266,199.00

    Immunotherapy has emerged as a promising method to treat several cancers. In 2012 the FDA approved a new immunotherapy agent, ipilimumab, for metastatic melanoma. Ipilimumab activates T-cells and glob ...

    SBIR Phase I 2013 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government